Web based Drug Database (1.07 Linux)

INDOMETACIN [RECTUM]

Names
Common Name	INDOMETACIN [RECTUM]
Other Name	INDOMETHACIN [RECTUM]
Pharmacological Group	NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
Chemical Name	Sodium 1-(4-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetate, trihydrate
Chemical Group

Attributes

Indications	Contraindications	Prescriber Cautions	Patient Cautions
Toxicity	Side Effects	Liver Disease	Renal Failure
Pregnancy	Lactation	Pharmacological Actions	Diagnostic Procedures
Drugs	Interactions

Indications

Low back pain
Pericardial rub
Gout
Dysmenorrhoea
Rheumatoid arthritis
Osteoarthritis
Ankylosing spondylitis
Capsulitis
Tendinitis
Synovitis and tenosynovitis
Bursitis
Musculoskeletal pain
Postoperative pain

Contraindications

Asthma
Peptic ulcer
Analgesic allergy
Chronic asthmatic bronchitis
Peptic ulcer of oesophagus
Gastric ulcer
Duodenal ulcer
Peptic ulcer - (PU) site unspecified
Gastrojejunal ulcer
Gastritis and duodenitis
Rectal haemorrhage
Proctitis
Indometacin poisoning
Angioneurotic oedema
Adverse reaction to antirheumatics
Adverse reaction to indometacin
Airways obstruction reversible
Non-steroidal anti-inflammatory drugs contraindicated

Prescriber Cautions

Consult current official advice regarding INDOMETACIN [RECTUM]
Regular ophthalmic examination advised during prolonged treatment with INDOMETACIN [RECTUM]
Regular haematological examination advised during prolonged treatment with INDOMETACIN [RECTUM]

Patient Cautions

See information on products containing INDOMETACIN [RECTUM] for specific advice for patients

Toxicity

- None Listed -

Side Effects

Dyspepsia - Very Common
Abdominal pain - Common
Depression - Common
Dizziness - Common
Fatigue/asthenia - Common
Headache - Common
Light-headedness - Common
Agranulocytosis - Uncommon
Allergic purpura - Uncommon
Angioneurotic oedema - Uncommon
Anxiousness - Uncommon
Aplastic anaemia - Uncommon
Blurred Vision - Uncommon
Bone marrow suppression - Uncommon
Cardiac dysrhythmias - Uncommon
Chest pain - Uncommon
Confusion - Uncommon
Congestive heart failure - Uncommon
Convulsions - Uncommon
Corneal deposits - Uncommon
Defibrination syndrome - Uncommon
Drowsiness - Uncommon
Ecchymoses - Uncommon
Erythema multiforme - Uncommon
Exfoliative dermatitis - Uncommon
Haemolytic anaemia - Uncommon
Hypotension - Uncommon
Insomnia - Uncommon
Involuntary movements - Uncommon
Leucopenia - Uncommon
Palpitations - Uncommon
Paraesthesia - Uncommon
Peptic ulcer symptoms - Uncommon
Peripheral autonomic neuropathy - Uncommon
Petechiae - Uncommon
Pulmonary oedema - Uncommon
Stevens-Johnson syndrome - Uncommon
Tachycardia - Uncommon
Toxic epidermal necrolysis - Uncommon
Abnormal uterine bleeding - Rare
Acute hepatitis - Rare
Breast tenderness - Rare
Bronchospasm - Rare
Deafness - Rare
Dyspnoea - Rare
Epistaxis - Rare
Excessive flatulence - Rare
Excessive sweating - Rare
Flushing - Rare
Gastrointestinal haemorrhage - Rare
Glycosuria - Rare
Gynaecomastia - Rare
Hyperglycaemia - Rare
Hyperkalaemia - Rare
Interstitial nephritis - Rare
Intestinal obstruction - Rare
Jaundice - Rare
Liver function tests abnormal - Rare
Mastodynia - pain in breast - Rare
Nephrotic syndrome - Rare
Oral aphthae - Rare
Proteinuria - Rare
Renal function tests abnormal - Rare
Appetite loss - anorexia
Black faeces
Blood in urine - haematuria
Blood urea raised
Constipation
Diarrhoea
Epigastric pain
Erythema nodosum
Hearing difficulty
Hypertension
Itching
Nausea
Oedema
Patches of alopecia
Rash
Thrombocytopenia
Tinnitus
Vomiting

Liver Disease

Avoid INDOMETACIN [RECTUM] in severe liver disease
INDOMETACIN [RECTUM] causes sodium and water retention in liver disease
INDOMETACIN [RECTUM] - increased risk of gastrointestinal bleeding in liver disease

Renal Failure

Avoid INDOMETACIN [RECTUM] if possible in mild renal failure
Manufacturer advises reduce dose of INDOMETACIN [RECTUM] in renal failure
INDOMETACIN [RECTUM] - reduces renal function in renal failure
INDOMETACIN [RECTUM] - sodium and water retention in renal failure

Pregnancy

With regular doses of INDOMETACIN [RECTUM] - increased risk of closure of fetal ductus arteriosus in utero & possible persistent pulmonary hypertension of the newborn
Delayed onset & increased duration of labour with increased blood loss
Avoid INDOMETACIN [RECTUM] in the 1st TRIMESTER of pregnancy
Avoid INDOMETACIN [RECTUM] in the 3rd TRIMESTER of pregnancy
Manufacturer advises toxicity of INDOMETACIN [RECTUM] in pregnancy in animal studies

Lactation

INDOMETACIN [RECTUM] - one case of convulsions reported in an infant
Manufacturers advise that mothers should not breast feed during treatment with INDOMETACIN [RECTUM]

Pharmacological Actions

ANALGESIC effect
ANTIINFLAMMATORY effect
ANTIPYRETIC effect
CYCLOOXYGENASE INHIBITOR effect

Diagnostic Procedures

- None Listed -

Drugs containing INDOMETACIN [RECTUM]

INDOMETACIN 100mg supps

Interacting Ingredients

ACEBUTOLOL
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of ACEBUTOLOL. Potential risk. Monitor
ACECLOFENAC
Likely interaction of ACECLOFENAC increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. May need to avoid combination
ACEMETACIN
Likely interaction of ACEMETACIN increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. May need to avoid combination
ACENOCOUMAROL
Theoretical potential for INDOMETACIN [RECTUM] increasing the ANTICOAGULANT effect of ACENOCOUMAROL. Moderate risk. Monitor
ALOXIPRIN
Likely interaction of INDOMETACIN [RECTUM] increasing the GASTRIC IRRITANT effect of ALOXIPRIN. Moderate risk. May need to avoid combination
AMIKACIN
Likely interaction of INDOMETACIN [RECTUM] increasing the SERUM LEVEL of AMIKACIN. Moderate risk. Monitor
AMINOPHYLLINE
Infrequent reports of INDOMETACIN [RECTUM] reducing the BRONCHODILATOR effect of AMINOPHYLLINE. Moderate risk. Avoid
ASPIRIN
Likely interaction of ASPIRIN increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. May need to avoid combination
ASPIRIN
Likely interaction of INDOMETACIN [RECTUM] increasing the GASTRIC IRRITANT effect of ASPIRIN. Moderate risk. May need to avoid combination
ASPIRIN [RECTUM]
Likely interaction of ASPIRIN [RECTUM] increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. May need to avoid combination
ASPIRIN [RECTUM]
Likely interaction of INDOMETACIN [RECTUM] increasing the GASTRIC IRRITANT effect of ASPIRIN [RECTUM]. Moderate risk. May need to avoid combination
ATENOLOL [ORAL]
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of ATENOLOL [ORAL]. Potential risk. Monitor
ATENOLOL [PARENTERAL]
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of ATENOLOL [PARENTERAL]. Potential risk. Monitor
AZAPROPAZONE
Likely interaction of INDOMETACIN [RECTUM] increasing the GASTRIC IRRITANT effect of AZAPROPAZONE. Moderate risk. May need to avoid combination
BAMBUTEROL HYDROCHLORIDE
Infrequent reports of INDOMETACIN [RECTUM] reducing the BRONCHODILATOR effect of BAMBUTEROL HYDROCHLORIDE. Moderate risk. Avoid
BCG VACCINE LIVE
Infrequent reports of INDOMETACIN [RECTUM] increasing the ANTIMICROBIAL side effect of BCG VACCINE LIVE. Usually no risk. Usually no action necessary
BECLOMETASONE [INHALED]
Infrequent reports of INDOMETACIN [RECTUM] reducing the BRONCHODILATOR effect of BECLOMETASONE [INHALED]. Moderate risk. Avoid
BENDROFLUMETHIAZIDE
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of BENDROFLUMETHIAZIDE. Moderate risk. Monitor
BENORILATE
Likely interaction of BENORILATE increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. May need to avoid combination
BENZTHIAZIDE
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of BENZTHIAZIDE. Moderate risk. Monitor
BETAMETHASONE
Likely interaction of BETAMETHASONE increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. Monitor
BETAMETHASONE [INHALED]
Infrequent reports of INDOMETACIN [RECTUM] reducing the BRONCHODILATOR effect of BETAMETHASONE [INHALED]. Moderate risk. Avoid
BETAXOLOL
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of BETAXOLOL. Potential risk. Monitor
BISMUTH CHELATE
Likely interaction of INDOMETACIN [RECTUM] reducing the ULCER HEALING effect of BISMUTH CHELATE. Moderate risk. Avoid
BISOPROLOL FUMARATE
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of BISOPROLOL FUMARATE. Potential risk. Monitor
BUDESONIDE [GASTROINTESTINAL]
Likely interaction of BUDESONIDE [GASTROINTESTINAL] increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. Monitor
BUDESONIDE [INHALED]
Infrequent reports of INDOMETACIN [RECTUM] reducing the BRONCHODILATOR effect of BUDESONIDE [INHALED]. Moderate risk. Avoid
BUFYLLINE
Infrequent reports of INDOMETACIN [RECTUM] reducing the BRONCHODILATOR effect of BUFYLLINE. Moderate risk. Avoid
BUMETANIDE
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of BUMETANIDE. Moderate risk. Monitor
CANDESARTAN CILEXETIL
Likely interaction of INDOMETACIN [RECTUM] increasing the NEPHROTOXICITY of CANDESARTAN CILEXETIL. Potential risk. Monitor
CAPTOPRIL
Theoretical potential for INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of CAPTOPRIL. Potential risk. Monitor
CARBENOXOLONE
Likely interaction of INDOMETACIN [RECTUM] reducing the ULCER HEALING effect of CARBENOXOLONE. Moderate risk. Avoid
CARTEOLOL HYDROCHLORIDE
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of CARTEOLOL HYDROCHLORIDE. Potential risk. Monitor
CARVEDILOL
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of CARVEDILOL. Potential risk. Monitor
CELIPROLOL HYDROCHLORIDE
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of CELIPROLOL HYDROCHLORIDE. Potential risk. Monitor
CHLOROTHIAZIDE
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of CHLOROTHIAZIDE. Moderate risk. Monitor
CHLORPROPAMIDE
Infrequent reports of INDOMETACIN [RECTUM] increasing the HYPOGLYCAEMIC effect of CHLORPROPAMIDE. Usually no risk. Usually no action necessary
CHLORTALIDONE
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of CHLORTALIDONE. Moderate risk. Monitor
CHOLINE MAGNESIUM TRISALICYLATE
Likely interaction of CHOLINE MAGNESIUM TRISALICYLATE increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. May need to avoid combination
CHOLINE THEOPHYLLINATE
Infrequent reports of INDOMETACIN [RECTUM] reducing the BRONCHODILATOR effect of CHOLINE THEOPHYLLINATE. Moderate risk. Avoid
CICLOSPORIN
Theoretical potential for INDOMETACIN [RECTUM] reducing the IMMUNOSUPPRESSANT effect of CICLOSPORIN. Usually no risk. Usually no action necessary
CILAZAPRIL
Theoretical potential for INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of CILAZAPRIL. Potential risk. Monitor
CIMETIDINE
Likely interaction of INDOMETACIN [RECTUM] reducing the ULCER HEALING effect of CIMETIDINE. Moderate risk. Avoid
CLOPAMIDE
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of CLOPAMIDE. Moderate risk. Monitor
CLOPIDOGREL
Theoretical potential for INDOMETACIN [RECTUM] increasing the PLATELET ANTAGONIST effect of CLOPIDOGREL. Moderate risk. May need to avoid combination
COCAINE HYDROCHLORIDE
Infrequent reports of COCAINE HYDROCHLORIDE increasing the NEPHROTOXICITY of INDOMETACIN [RECTUM]. Usually no risk. Usually no action necessary
COCAINE HYDROCHLORIDE [EYE]
Infrequent reports of COCAINE HYDROCHLORIDE [EYE] increasing the NEPHROTOXICITY of INDOMETACIN [RECTUM]. Usually no risk. Usually no action necessary
COCAINE HYDROCHLORIDE [NOSE]
Infrequent reports of COCAINE HYDROCHLORIDE [NOSE] increasing the NEPHROTOXICITY of INDOMETACIN [RECTUM]. Usually no risk. Usually no action necessary
CORTISONE ACETATE
Likely interaction of CORTISONE ACETATE increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. Monitor
CROMOGLICATE [INHALED]
Infrequent reports of INDOMETACIN [RECTUM] reducing the BRONCHODILATOR effect of CROMOGLICATE [INHALED]. Moderate risk. Avoid
CYCLOPENTHIAZIDE
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of CYCLOPENTHIAZIDE. Moderate risk. Monitor
DANAPAROID SODIUM
Theoretical potential for INDOMETACIN [RECTUM] increasing the ANTICOAGULANT effect of DANAPAROID SODIUM. Moderate risk. May need to avoid combination
DEGLYCYRRHIZINISED LIQUORICE
Likely interaction of INDOMETACIN [RECTUM] reducing the ULCER HEALING effect of DEGLYCYRRHIZINISED LIQUORICE. Moderate risk. Avoid
DEXAMETHASONE [ORAL]
Likely interaction of DEXAMETHASONE [ORAL] increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. Monitor
DEXAMETHASONE [PARENTERAL]
Likely interaction of DEXAMETHASONE [PARENTERAL] increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. Monitor
DEXIBUPROFEN
Likely interaction of INDOMETACIN [RECTUM] increasing the GASTRIC IRRITANT effect of DEXIBUPROFEN. Moderate risk. May need to avoid combination
DEXKETOPROFEN
Likely interaction of DEXKETOPROFEN increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. May need to avoid combination
DIAZEPAM
Theoretical potential for INDOMETACIN [RECTUM] increasing the CNS TOXICITY of DIAZEPAM. Usually no risk. Usually no action necessary
DIAZEPAM [EMULSION]
Theoretical potential for INDOMETACIN [RECTUM] increasing the CNS TOXICITY of DIAZEPAM [EMULSION]. Usually no risk. Usually no action necessary
DICLOFENAC POTASSIUM
Likely interaction of DICLOFENAC POTASSIUM increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. May need to avoid combination
DICLOFENAC SODIUM [ORAL]
Likely interaction of DICLOFENAC SODIUM [ORAL] increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. May need to avoid combination
DICLOFENAC SODIUM [PARENTERAL]
Likely interaction of DICLOFENAC SODIUM [PARENTERAL] increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. May need to avoid combination
DICLOFENAC SODIUM [RECTUM]
Likely interaction of DICLOFENAC SODIUM [RECTUM] increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. May need to avoid combination
DIFLUNISAL
Infrequent reports of DIFLUNISAL increasing the SERUM LEVEL of INDOMETACIN [RECTUM]. Potential risk. Avoid
DIFLUNISAL
Likely interaction of INDOMETACIN [RECTUM] increasing the GASTRIC IRRITANT effect of DIFLUNISAL. Moderate risk. May need to avoid combination
DIGOXIN
Theoretical potential for INDOMETACIN [RECTUM] increasing the SERUM LEVEL of DIGOXIN. Potential risk. Monitor
DIPROPHYLLINE
Infrequent reports of INDOMETACIN [RECTUM] reducing the BRONCHODILATOR effect of DIPROPHYLLINE. Moderate risk. Avoid
ENALAPRIL MALEATE
Theoretical potential for INDOMETACIN [RECTUM] reducing the ACE INHIBITOR effect of ENALAPRIL MALEATE. Potential risk. Monitor
ENOXAPARIN
Likely interaction of INDOMETACIN [RECTUM] increasing the ANTICOAGULANT effect of ENOXAPARIN. Moderate risk. May need to avoid combination
EPHEDRINE HYDROCHLORIDE
Infrequent reports of INDOMETACIN [RECTUM] reducing the BRONCHODILATOR effect of EPHEDRINE HYDROCHLORIDE. Moderate risk. Avoid
EPROSARTAN
Likely interaction of INDOMETACIN [RECTUM] increasing the NEPHROTOXICITY of EPROSARTAN. Potential risk. Monitor
ESMOLOL HYDROCHLORIDE
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of ESMOLOL HYDROCHLORIDE. Potential risk. Monitor
ESOMEPRAZOLE
Likely interaction of INDOMETACIN [RECTUM] reducing the ULCER HEALING effect of ESOMEPRAZOLE. Moderate risk. Avoid
ETODOLAC
Likely interaction of INDOMETACIN [RECTUM] increasing the GASTRIC IRRITANT effect of ETODOLAC. Moderate risk. May need to avoid combination
FAMOTIDINE
Likely interaction of INDOMETACIN [RECTUM] reducing the ULCER HEALING effect of FAMOTIDINE. Moderate risk. Avoid
FENBUFEN
Likely interaction of FENBUFEN increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. May need to avoid combination
FENOPROFEN
Likely interaction of FENOPROFEN increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. May need to avoid combination
FENOTEROL HYDROBROMIDE
Infrequent reports of INDOMETACIN [RECTUM] reducing the BRONCHODILATOR effect of FENOTEROL HYDROBROMIDE. Moderate risk. Avoid
FLUDROCORTISONE ACETATE
Likely interaction of FLUDROCORTISONE ACETATE increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. Monitor
FLURBIPROFEN
Likely interaction of INDOMETACIN [RECTUM] increasing the GASTRIC IRRITANT effect of FLURBIPROFEN. Moderate risk. May need to avoid combination
FLURBIPROFEN [RECTUM]
Likely interaction of INDOMETACIN [RECTUM] increasing the GASTRIC IRRITANT effect of FLURBIPROFEN [RECTUM]. Moderate risk. May need to avoid combination
FLUTICASONE [INHALED]
Infrequent reports of INDOMETACIN [RECTUM] reducing the BRONCHODILATOR effect of FLUTICASONE [INHALED]. Moderate risk. Avoid
FONDAPARINUX SODIUM
Likely interaction of INDOMETACIN [RECTUM] increasing the ANTICOAGULANT effect of FONDAPARINUX SODIUM. Moderate risk. May need to avoid combination
FORMOTEROL
Infrequent reports of INDOMETACIN [RECTUM] reducing the BRONCHODILATOR effect of FORMOTEROL. Moderate risk. Avoid
FUROSEMIDE
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of FUROSEMIDE. Moderate risk. Monitor
GENTAMICIN SULPHATE
Likely interaction of INDOMETACIN [RECTUM] increasing the SERUM LEVEL of GENTAMICIN SULPHATE. Moderate risk. Monitor
HALOPERIDOL
Infrequent reports of INDOMETACIN [RECTUM] increasing the CNS TOXICITY of HALOPERIDOL. Moderate risk. Monitor
HALOPERIDOL DECANOATE
Infrequent reports of INDOMETACIN [RECTUM] increasing the CNS TOXICITY of HALOPERIDOL DECANOATE. Moderate risk. Monitor
HYDRALAZINE HYDROCHLORIDE
Theoretical potential for INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of HYDRALAZINE HYDROCHLORIDE. Moderate risk. Monitor
HYDROCHLOROTHIAZIDE
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of HYDROCHLOROTHIAZIDE. Moderate risk. Monitor
HYDROCORTISONE
Likely interaction of HYDROCORTISONE increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. Monitor
HYDROCORTISONE SODIUM PHOSPHATE
Likely interaction of HYDROCORTISONE SODIUM PHOSPHATE increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. Monitor
HYDROCORTISONE SODIUM SUCCINATE
Likely interaction of HYDROCORTISONE SODIUM SUCCINATE increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. Monitor
HYDROFLUMETHIAZIDE
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of HYDROFLUMETHIAZIDE. Moderate risk. Monitor
IBUPROFEN
Likely interaction of INDOMETACIN [RECTUM] increasing the GASTRIC IRRITANT effect of IBUPROFEN. Moderate risk. May need to avoid combination
IBUPROFEN LYSINE
Likely interaction of INDOMETACIN [RECTUM] increasing the GASTRIC IRRITANT effect of IBUPROFEN LYSINE. Moderate risk. May need to avoid combination
IMIDAPRIL
Theoretical potential for INDOMETACIN [RECTUM] reducing the ACE INHIBITOR effect of IMIDAPRIL. Potential risk. Monitor
INDACATEROL
Infrequent reports of INDOMETACIN [RECTUM] reducing the BRONCHODILATOR effect of INDACATEROL. Moderate risk. Avoid
INDAPAMIDE
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of INDAPAMIDE. Moderate risk. Monitor
IRBESARTAN
Likely interaction of INDOMETACIN [RECTUM] increasing the NEPHROTOXICITY of IRBESARTAN. Potential risk. Monitor
ISOETARINE HYDROCHLORIDE
Infrequent reports of INDOMETACIN [RECTUM] reducing the BRONCHODILATOR effect of ISOETARINE HYDROCHLORIDE. Moderate risk. Avoid
ISOPRENALINE HYDROCHLORIDE
Infrequent reports of INDOMETACIN [RECTUM] reducing the BRONCHODILATOR effect of ISOPRENALINE HYDROCHLORIDE. Moderate risk. Avoid
ISOPRENALINE SULPHATE
Infrequent reports of INDOMETACIN [RECTUM] reducing the BRONCHODILATOR effect of ISOPRENALINE SULPHATE. Moderate risk. Avoid
KETOPROFEN
Likely interaction of INDOMETACIN [RECTUM] increasing the GASTRIC IRRITANT effect of KETOPROFEN. Moderate risk. May need to avoid combination
KETOPROFEN [RECTUM]
Likely interaction of INDOMETACIN [RECTUM] increasing the GASTRIC IRRITANT effect of KETOPROFEN [RECTUM]. Moderate risk. May need to avoid combination
KETOROLAC TROMETAMOL
Likely interaction of INDOMETACIN [RECTUM] increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
KETOTIFEN
Infrequent reports of INDOMETACIN [RECTUM] reducing the BRONCHODILATOR effect of KETOTIFEN. Moderate risk. Avoid
LABETALOL HYDROCHLORIDE
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of LABETALOL HYDROCHLORIDE. Moderate risk. Monitor
LANSOPRAZOLE
Likely interaction of INDOMETACIN [RECTUM] reducing the ULCER HEALING effect of LANSOPRAZOLE. Moderate risk. Avoid
LISINOPRIL
Theoretical potential for INDOMETACIN [RECTUM] reducing the ACE INHIBITOR effect of LISINOPRIL. Potential risk. Monitor
LITHIUM CARBONATE
Likely interaction of INDOMETACIN [RECTUM] increasing the SERUM LEVEL of LITHIUM CARBONATE. Potential risk. Monitor
LITHIUM CHLORIDE [PARENTERAL]
Likely interaction of INDOMETACIN [RECTUM] increasing the SERUM LEVEL of LITHIUM CHLORIDE [PARENTERAL]. Potential risk. Monitor
LITHIUM CITRATE
Likely interaction of INDOMETACIN [RECTUM] increasing the SERUM LEVEL of LITHIUM CITRATE. Potential risk. Monitor
LOSARTAN POTASSIUM
Likely interaction of INDOMETACIN [RECTUM] increasing the NEPHROTOXICITY of LOSARTAN POTASSIUM. Potential risk. Monitor
LYSINE ASPIRIN
Likely interaction of LYSINE ASPIRIN increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. May need to avoid combination
LYSINE ASPIRIN
Likely interaction of INDOMETACIN [RECTUM] increasing the GASTRIC IRRITANT effect of LYSINE ASPIRIN. Moderate risk. May need to avoid combination
MEASLES AND RUBELLA VACCINE LIVE
Infrequent reports of INDOMETACIN [RECTUM] increasing the ANTIMICROBIAL side effect of MEASLES AND RUBELLA VACCINE LIVE. Usually no risk. Usually no action necessary
MEASLES MUMPS AND RUBELLA VACCINE LIVE
Infrequent reports of INDOMETACIN [RECTUM] increasing the ANTIMICROBIAL side effect of MEASLES MUMPS AND RUBELLA VACCINE LIVE. Usually no risk. Usually no action necessary
MEASLES VACCINE LIVE
Infrequent reports of INDOMETACIN [RECTUM] increasing the ANTIMICROBIAL side effect of MEASLES VACCINE LIVE. Usually no risk. Usually no action necessary
MEFENAMIC ACID
Likely interaction of INDOMETACIN [RECTUM] increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. May need to avoid combination
MEFRUSIDE
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of MEFRUSIDE. Moderate risk. Monitor
MELOXICAM
Likely interaction of INDOMETACIN [RECTUM] increasing the GASTRIC IRRITANT effect of MELOXICAM. Moderate risk. May need to avoid combination
MELOXICAM [RECTUM]
Likely interaction of INDOMETACIN [RECTUM] increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. May need to avoid combination
MESALAZINE
Theoretical potential for INDOMETACIN [RECTUM] increasing the NEPHROTOXICITY of MESALAZINE. Potential risk. May need to avoid combination
METHYCLOTHIAZIDE
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of METHYCLOTHIAZIDE. Moderate risk. Monitor
METHYLEPHEDRINE
Infrequent reports of INDOMETACIN [RECTUM] reducing the BRONCHODILATOR effect of METHYLEPHEDRINE. Moderate risk. Avoid
METHYLPREDNISOLONE
Likely interaction of METHYLPREDNISOLONE increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. Monitor
METOLAZONE
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of METOLAZONE. Usually no risk. Usually no action necessary
METOPROLOL FUMARATE
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of METOPROLOL FUMARATE. Potential risk. Monitor
METOPROLOL TARTRATE
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of METOPROLOL TARTRATE. Potential risk. Monitor
MIFEPRISTONE
Theoretical potential for INDOMETACIN [RECTUM] increasing the PROSTANERGIC effect of MIFEPRISTONE. Potential risk. Avoid
MISOPROSTOL
Likely interaction of MISOPROSTOL increasing the SERUM LEVEL of INDOMETACIN [RECTUM]. Moderate risk. May need to avoid combination
MOEXIPRIL
Theoretical potential for INDOMETACIN [RECTUM] reducing the ACE INHIBITOR effect of MOEXIPRIL. Potential risk. Monitor
MONTELUKAST
Infrequent reports of INDOMETACIN [RECTUM] reducing the BRONCHODILATOR effect of MONTELUKAST. Moderate risk. Avoid
MUMPS VACCINE LIVE
Infrequent reports of INDOMETACIN [RECTUM] increasing the ANTIMICROBIAL side effect of MUMPS VACCINE LIVE. Usually no risk. Usually no action necessary
MUROMONAB CD3
Likely interaction of INDOMETACIN [RECTUM] increasing the CNS TOXICITY of MUROMONAB CD3. Potential risk. Monitor
NABUMETONE
Likely interaction of NABUMETONE increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. May need to avoid combination
NADOLOL
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of NADOLOL. Potential risk. Monitor
NAPROXEN
Likely interaction of NAPROXEN increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. May need to avoid combination
NAPROXEN SODIUM
Likely interaction of NAPROXEN SODIUM increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. May need to avoid combination
NAPROXEN [RECTUM]
Likely interaction of NAPROXEN [RECTUM] increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. May need to avoid combination
NEDOCROMIL SODIUM
Infrequent reports of INDOMETACIN [RECTUM] reducing the BRONCHODILATOR effect of NEDOCROMIL SODIUM. Moderate risk. Avoid
NIZATIDINE
Likely interaction of INDOMETACIN [RECTUM] reducing the ULCER HEALING effect of NIZATIDINE. Moderate risk. Avoid
OLMESARTAN MEDOXOMIL
Likely interaction of INDOMETACIN [RECTUM] increasing the NEPHROTOXICITY of OLMESARTAN MEDOXOMIL. Potential risk. Monitor
OMEPRAZOLE [ORAL]
Likely interaction of INDOMETACIN [RECTUM] reducing the ULCER HEALING effect of OMEPRAZOLE [ORAL]. Moderate risk. Avoid
OMEPRAZOLE [PARENTERAL]
Likely interaction of INDOMETACIN [RECTUM] reducing the ULCER HEALING effect of OMEPRAZOLE [PARENTERAL]. Moderate risk. Avoid
ORAL POLIOMYELITIS VACCINE LIVE
Infrequent reports of INDOMETACIN [RECTUM] increasing the ANTIMICROBIAL side effect of ORAL POLIOMYELITIS VACCINE LIVE. Usually no risk. Usually no action necessary
ORCIPRENALINE
Infrequent reports of INDOMETACIN [RECTUM] reducing the BRONCHODILATOR effect of ORCIPRENALINE. Moderate risk. Avoid
ORCIPRENALINE [INHALED]
Infrequent reports of INDOMETACIN [RECTUM] reducing the BRONCHODILATOR effect of ORCIPRENALINE [INHALED]. Moderate risk. Avoid
OXPRENOLOL HYDROCHLORIDE
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of OXPRENOLOL HYDROCHLORIDE. Potential risk. Monitor
PANTOPRAZOLE
Likely interaction of INDOMETACIN [RECTUM] reducing the ULCER HEALING effect of PANTOPRAZOLE. Moderate risk. Avoid
PENBUTOLOL SULPHATE
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of PENBUTOLOL SULPHATE. Potential risk. Monitor
PENICILLAMINE
Theoretical potential for INDOMETACIN [RECTUM] increasing the SERUM LEVEL of PENICILLAMINE. Moderate risk. Monitor
PERINDOPRIL ARGININE
Theoretical potential for INDOMETACIN [RECTUM] reducing the ACE INHIBITOR effect of PERINDOPRIL ARGININE. Potential risk. Monitor
PERINDOPRIL ERBUMINE
Theoretical potential for INDOMETACIN [RECTUM] reducing the ACE INHIBITOR effect of PERINDOPRIL ERBUMINE. Potential risk. Monitor
PHENINDIONE
Theoretical potential for INDOMETACIN [RECTUM] increasing the ANTICOAGULANT effect of PHENINDIONE. Moderate risk. Monitor
PHENYLBUTAZONE
Likely interaction of PHENYLBUTAZONE increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. May need to avoid combination
PHENYLPROPANOLAMINE HYDROCHLORIDE
Infrequent reports of INDOMETACIN [RECTUM] increasing the HYPERTENSIVE effect of PHENYLPROPANOLAMINE HYDROCHLORIDE. Usually no risk. Usually no action necessary
PINDOLOL
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of PINDOLOL. Potential risk. Monitor
PIRBUTEROL
Infrequent reports of INDOMETACIN [RECTUM] reducing the BRONCHODILATOR effect of PIRBUTEROL. Moderate risk. Avoid
PIRETANIDE
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of PIRETANIDE. Usually no risk. Usually no action necessary
PIROXICAM
Likely interaction of PIROXICAM increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. May need to avoid combination
PIROXICAM [RECTUM]
Likely interaction of PIROXICAM [RECTUM] increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. May need to avoid combination
PIROXICAM-BETADEX
Likely interaction of PIROXICAM-BETADEX increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. May need to avoid combination
POLYTHIAZIDE
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of POLYTHIAZIDE. Moderate risk. Monitor
PRACTOLOL
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of PRACTOLOL. Potential risk. Monitor
PRAZOSIN HYDROCHLORIDE
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of PRAZOSIN HYDROCHLORIDE. Moderate risk. Monitor
PREDNISOLONE
Likely interaction of PREDNISOLONE increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. Monitor
PREDNISOLONE ACETATE
Likely interaction of PREDNISOLONE ACETATE increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. Monitor
PREDNISOLONE SODIUM PHOSPHATE
Likely interaction of PREDNISOLONE SODIUM PHOSPHATE increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. Monitor
PREDNISONE
Likely interaction of PREDNISONE increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. Monitor
PROBENECID
Likely interaction of PROBENECID increasing the SERUM LEVEL of INDOMETACIN [RECTUM]. Potential risk. Monitor
PROPRANOLOL HYDROCHLORIDE
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of PROPRANOLOL HYDROCHLORIDE. Potential risk. Monitor
QUINAPRIL
Theoretical potential for INDOMETACIN [RECTUM] reducing the ACE INHIBITOR effect of QUINAPRIL. Potential risk. Monitor
RABEPRAZOLE
Likely interaction of INDOMETACIN [RECTUM] reducing the ULCER HEALING effect of RABEPRAZOLE. Moderate risk. Avoid
RAMIPRIL
Theoretical potential for INDOMETACIN [RECTUM] reducing the ACE INHIBITOR effect of RAMIPRIL. Potential risk. Monitor
RANITIDINE
Likely interaction of INDOMETACIN [RECTUM] reducing the ULCER HEALING effect of RANITIDINE. Moderate risk. Avoid
RANITIDINE BISMUTH CITRATE
Likely interaction of INDOMETACIN [RECTUM] reducing the ULCER HEALING effect of RANITIDINE BISMUTH CITRATE. Moderate risk. Avoid
REPROTEROL HYDROCHLORIDE
Infrequent reports of INDOMETACIN [RECTUM] reducing the BRONCHODILATOR effect of REPROTEROL HYDROCHLORIDE. Moderate risk. Avoid
RIMITEROL HYDROBROMIDE
Infrequent reports of INDOMETACIN [RECTUM] reducing the BRONCHODILATOR effect of RIMITEROL HYDROBROMIDE. Moderate risk. Avoid
RITODRINE HYDROCHLORIDE
Infrequent reports of INDOMETACIN [RECTUM] reducing the BRONCHODILATOR effect of RITODRINE HYDROCHLORIDE. Moderate risk. Avoid
RUBELLA VACCINE LIVE
Infrequent reports of INDOMETACIN [RECTUM] increasing the ANTIMICROBIAL side effect of RUBELLA VACCINE LIVE. Usually no risk. Usually no action necessary
SALBUTAMOL
Infrequent reports of INDOMETACIN [RECTUM] reducing the BRONCHODILATOR effect of SALBUTAMOL. Moderate risk. Avoid
SALBUTAMOL [INHALED]
Infrequent reports of INDOMETACIN [RECTUM] reducing the BRONCHODILATOR effect of SALBUTAMOL [INHALED]. Moderate risk. Avoid
SALICYLAMIDE
Likely interaction of SALICYLAMIDE increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. May need to avoid combination
SALIX
Likely interaction of SALIX increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. May need to avoid combination
SALMETEROL XINAFOATE
Infrequent reports of INDOMETACIN [RECTUM] reducing the BRONCHODILATOR effect of SALMETEROL XINAFOATE. Moderate risk. Avoid
SALSALATE
Likely interaction of SALSALATE increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. May need to avoid combination
SODIUM FOSINOPRIL
Theoretical potential for INDOMETACIN [RECTUM] reducing the ACE INHIBITOR effect of SODIUM FOSINOPRIL. Potential risk. Monitor
SODIUM SALICYLATE
Likely interaction of SODIUM SALICYLATE increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. May need to avoid combination
SOTALOL HYDROCHLORIDE
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of SOTALOL HYDROCHLORIDE. Potential risk. Monitor
SUCRALFATE
Likely interaction of INDOMETACIN [RECTUM] reducing the ULCER HEALING effect of SUCRALFATE. Moderate risk. Avoid
SULINDAC
Likely interaction of SULINDAC increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. May need to avoid combination
TACROLIMUS
Infrequent reports of INDOMETACIN [RECTUM] increasing the NEPHROTOXICITY of TACROLIMUS. Moderate risk. Monitor
TELMISARTAN
Likely interaction of INDOMETACIN [RECTUM] increasing the NEPHROTOXICITY of TELMISARTAN. Potential risk. Monitor
TENOXICAM
Likely interaction of TENOXICAM increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. May need to avoid combination
TERAZOSIN HYDROCHLORIDE
Theoretical potential for INDOMETACIN [RECTUM] reducing the ALPHA ANTAGONIST effect of TERAZOSIN HYDROCHLORIDE. Moderate risk. Monitor
TERBUTALINE
Infrequent reports of INDOMETACIN [RECTUM] reducing the BRONCHODILATOR effect of TERBUTALINE. Moderate risk. Avoid
TERBUTALINE [INHALED]
Infrequent reports of INDOMETACIN [RECTUM] reducing the BRONCHODILATOR effect of TERBUTALINE [INHALED]. Moderate risk. Avoid
THEOPHYLLINE
Infrequent reports of INDOMETACIN [RECTUM] reducing the BRONCHODILATOR effect of THEOPHYLLINE. Moderate risk. Avoid
TIAPROFENIC ACID
Likely interaction of INDOMETACIN [RECTUM] increasing the GASTRIC IRRITANT effect of TIAPROFENIC ACID. Moderate risk. May need to avoid combination
TILUDRONATE
Likely interaction of INDOMETACIN [RECTUM] reducing the GASTRO-INTESTINAL ABSORPTION of TILUDRONATE. Moderate risk. May need to avoid combination
TIMOLOL
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of TIMOLOL. Potential risk. Monitor
TINZAPARIN SODIUM
Likely interaction of INDOMETACIN [RECTUM] increasing the ANTICOAGULANT effect of TINZAPARIN SODIUM. Moderate risk. May need to avoid combination
TOLFENAMIC ACID
Likely interaction of TOLFENAMIC ACID increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. May need to avoid combination
TOLMETIN
Likely interaction of TOLMETIN increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. May need to avoid combination
TRANDOLAPRIL
Theoretical potential for INDOMETACIN [RECTUM] reducing the ACE INHIBITOR effect of TRANDOLAPRIL. Potential risk. Monitor
TRIAMCINOLONE ACETONIDE
Likely interaction of TRIAMCINOLONE ACETONIDE increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. Monitor
TRIAMTERENE
Infrequent reports of INDOMETACIN [RECTUM] increasing the NEPHROTOXICITY of TRIAMTERENE. Potential risk. Avoid
TULOBUTEROL HYDROCHLORIDE
Infrequent reports of INDOMETACIN [RECTUM] reducing the BRONCHODILATOR effect of TULOBUTEROL HYDROCHLORIDE. Moderate risk. Avoid
TYPHOID VACCINE LIVE
Infrequent reports of INDOMETACIN [RECTUM] increasing the ANTIMICROBIAL side effect of TYPHOID VACCINE LIVE. Usually no risk. Usually no action necessary
VALSARTAN
Likely interaction of INDOMETACIN [RECTUM] increasing the NEPHROTOXICITY of VALSARTAN. Potential risk. Monitor
VANCOMYCIN [PARENTERAL]
Likely interaction of INDOMETACIN [RECTUM] increasing the ANTIMICROBIAL effect of VANCOMYCIN [PARENTERAL]. Moderate risk. Monitor
VARICELLA ZOSTER VACCINE LIVE
Infrequent reports of INDOMETACIN [RECTUM] increasing the ANTIMICROBIAL side effect of VARICELLA ZOSTER VACCINE LIVE. Usually no risk. Usually no action necessary
WARFARIN SODIUM
Theoretical potential for INDOMETACIN [RECTUM] increasing the ANTICOAGULANT effect of WARFARIN SODIUM. Moderate risk. Monitor
XIPAMIDE
Likely interaction of INDOMETACIN [RECTUM] reducing the HYPOTENSIVE effect of XIPAMIDE. Moderate risk. Monitor
YELLOW FEVER VACCINE LIVE
Infrequent reports of INDOMETACIN [RECTUM] increasing the ANTIMICROBIAL side effect of YELLOW FEVER VACCINE LIVE. Usually no risk. Usually no action necessary
ZAFIRLUKAST
Infrequent reports of INDOMETACIN [RECTUM] reducing the BRONCHODILATOR effect of ZAFIRLUKAST. Moderate risk. Avoid